1. MAIA
  2. Topics
  3. Heart Failure
  4. References

Heart Failure

Therapeutic Brief

  1. Utilisation analysis of PBS-listed medicines for heart failure (2024).
  2. Chan Y-K, Tuttle C, Ball J, et al. Current and projected burden of heart failure in the Australian adult population: a substantive but still ill-defined major health issue. BMC Health Services Research. 2016;16:1-10.
  3. Supply and Demand Study: General Practitioners in Australia (2024).
  4. Sabbah HN. Silent disease progression in clinically stable heart failure. European Journal of Heart Failure. 2017;19(4):469-478.
  5. Al-Omary MS, Davies AJ, Evans T-J, et al. Mortality and readmission following hospitalisation for heart failure in Australia: a systematic review and meta-analysis. Heart, Lung and Circulation. 2018;27(8):917-927.
  6. Wang N, Hales S, Tofler G. 15-year trends in patients hospitalised with heart failure and enrolled in an Australian heart failure management program. Heart, Lung and Circulation. 2019;28(11):1646-1654.
  7. Atherton JJ, Sindone A, De Pasquale CG, et al. National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: guidelines for the prevention, detection, and management of heart failure in Australia 2018. Heart, Lung and Circulation. 2018;27(10):1123-1208.
  8. Wiley JF, Chan Y-K, Ahamed Y, et al. Multimorbidity and the risk of all-cause 30-day readmission in the setting of multidisciplinary Management of Chronic Heart Failure: a retrospective analysis of 830 hospitalized patients in Australia. Journal of Cardiovascular Nursing. 2018;33(5):437-445.
  9. Therapeutic Guidelines. Heart failure with reduced ejection fraction (HFrEF). Accessed 11 October 2024.
  10. Brownell NK, Ziaeian B, Fonarow GC. The gap to fill: rationale for rapid initiation and optimal titration of comprehensive disease-modifying medical therapy for heart failure with reduced ejection fraction. Cardiac Failure Review. 2021;7
  11. Maddox TM, Januzzi Jr JL, Allen LA, et al. 2024 ACC Expert Consensus Decision Pathway for Treatment of Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee. Journal of the American College of Cardiology. 2024;83(15):1444-1488.
  12. Sindone AP, De Pasquale C, Amerena J, et al. Consensus statement on the current pharmacological prevention and management of heart failure. Medical Journal of Australia. 2022;217(4):212-217.
  13. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. European heart journal. 2021;42(36):3599-3726.
  14. Savage HO, Dimarco AD, Li B, et al. Sequencing of medical therapy in heart failure with a reduced ejection fraction. Heart. 2023;109(7):511-518.
  15. Vaduganathan M, Claggett BL, Jhund PS, et al. Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials. The Lancet. 2020;396(10244):121-128.
  16. Yancy CW, Januzzi JL, Allen LA, et al. 2017 ACC expert consensus decision pathway for optimization of heart failure treatment: answers to 10 pivotal issues about heart failure with reduced ejection fraction: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. Journal of the American College of Cardiology. 2018;71(2):201-230.
  17. Therapeutic Guidelines. Overview of heart failure Accessed 22 October 2024.
  18. Velazquez EJ, Morrow DA, DeVore AD, et al. Angiotensin–neprilysin inhibition in acute decompensated heart failure. New England Journal of Medicine. 2019;380(6):539-548.
  19. Pharmaceutical Benefits Scheme. Sacubitril + Valsartan Accessed November, 2024. https://www.pbs.gov.au/medicine/item/11122J-11123K-11131W-13445P-13511D-13570F
  20. Masarone D, Martucci ML, Errigo V, Pacileo G. The use of β-blockers in heart failure with reduced ejection fraction. Journal of Cardiovascular Development and Disease. 2021;8(9):101.
  21. Jhund PS, Talebi A, Henderson AD, et al. Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis. The Lancet. 2024;404(10458):1119-1131.
  22. Geng C, Mao Y-C, Qi S-f, et al. Mineralocorticoid receptor antagonists for chronic heart failure: a meta-analysis focusing on the number needed to treat. Frontiers in Cardiovascular Medicine. 2023;10:1236008.
  23. Vaduganathan M, Docherty KF, Claggett BL, et al. SGLT2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. The Lancet. 2022;400(10354):757-767.
  24. Mebazaa A, Davison B, Chioncel O, et al. Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial. The Lancet. 2022;400(10367):1938-1952.
  25. Murphy SP, Ibrahim NE, Januzzi JL. Heart failure with reduced ejection fraction: a review. JAMA. 2020;324(5):488-504.
  26. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Journal of the American College of Cardiology. 2022;79(17):e263-e421.
  27. Marti CN, Fonarow GC, Anker SD, et al. Medication dosing for heart failure with reduced ejection fraction—opportunities and challenges. European journal of heart failure. 2019;21(3):286-296.
  28. Australian Medicines Handbook. Aldosterone antagonists https://amhonline.amh.net.au/chapters/cardiovascular-drugs/drugs-heart-failure/aldosterone-antagonists?menu=vertical
  29. McDonagh TA, Metra M, Adamo M, et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal. 2023;44(37):3627-3639.
  30. Roughead EE, Barratt JD, Ramsay E, et al. The effectiveness of collaborative medicine reviews in delaying time to next hospitalization for patients with heart failure in the practice setting: results of a cohort study. Circulation: Heart Failure. 2009;2(5):424-428.
  31. Vitry AI, Nguyen TA, Ramsay EN, et al. General practitioner management plans delaying time to next potentially preventable hospitalisation for patients with heart failure. Internal Medicine Journal. 2014;44(11):1117-1123.